IL213742A0 - Substituted quinazoline compounds - Google Patents

Substituted quinazoline compounds

Info

Publication number
IL213742A0
IL213742A0 IL213742A IL21374211A IL213742A0 IL 213742 A0 IL213742 A0 IL 213742A0 IL 213742 A IL213742 A IL 213742A IL 21374211 A IL21374211 A IL 21374211A IL 213742 A0 IL213742 A0 IL 213742A0
Authority
IL
Israel
Prior art keywords
quinazoline compounds
substituted quinazoline
substituted
compounds
quinazoline
Prior art date
Application number
IL213742A
Other languages
English (en)
Original Assignee
Fovea Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41735344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL213742(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fovea Pharmaceuticals filed Critical Fovea Pharmaceuticals
Publication of IL213742A0 publication Critical patent/IL213742A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL213742A 2008-12-29 2011-06-23 Substituted quinazoline compounds IL213742A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08360043 2008-12-29
PCT/EP2009/067494 WO2010076238A1 (en) 2008-12-29 2009-12-18 Substituted quinazoline compounds

Publications (1)

Publication Number Publication Date
IL213742A0 true IL213742A0 (en) 2011-07-31

Family

ID=41735344

Family Applications (1)

Application Number Title Priority Date Filing Date
IL213742A IL213742A0 (en) 2008-12-29 2011-06-23 Substituted quinazoline compounds

Country Status (23)

Country Link
US (1) US8389530B2 (cg-RX-API-DMAC7.html)
EP (1) EP2381943A1 (cg-RX-API-DMAC7.html)
JP (1) JP2012514020A (cg-RX-API-DMAC7.html)
KR (1) KR20110120878A (cg-RX-API-DMAC7.html)
CN (1) CN102333533A (cg-RX-API-DMAC7.html)
AU (1) AU2009334869A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0924067A2 (cg-RX-API-DMAC7.html)
CA (1) CA2748319A1 (cg-RX-API-DMAC7.html)
CO (1) CO6390105A2 (cg-RX-API-DMAC7.html)
CR (1) CR20110368A (cg-RX-API-DMAC7.html)
DO (1) DOP2011000209A (cg-RX-API-DMAC7.html)
EA (1) EA019110B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP11011204A (cg-RX-API-DMAC7.html)
IL (1) IL213742A0 (cg-RX-API-DMAC7.html)
MA (1) MA32968B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011007064A (cg-RX-API-DMAC7.html)
NI (1) NI201100134A (cg-RX-API-DMAC7.html)
NZ (1) NZ593949A (cg-RX-API-DMAC7.html)
PE (1) PE20120424A1 (cg-RX-API-DMAC7.html)
SG (1) SG172415A1 (cg-RX-API-DMAC7.html)
TN (1) TN2011000319A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010076238A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201104777B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081960A1 (es) 2010-06-22 2012-10-31 Fovea Pharmaceuticals Sa Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
SG11201500125QA (en) 2012-07-11 2015-02-27 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
RS63405B1 (sr) 2013-10-25 2022-08-31 Blueprint Medicines Corp Inhibitori receptora faktora rasta fibroblasta
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
KR101715448B1 (ko) * 2014-07-16 2017-03-20 주식회사 큐리언트 염증성 질환 치료용 화합물
SG11201705192PA (en) 2014-12-24 2017-07-28 Gilead Sciences Inc Fused pyrimidine compounds for the treatment of hiv
TWI699355B (zh) 2014-12-24 2020-07-21 美商基利科學股份有限公司 喹唑啉化合物
BR112017013440A2 (pt) 2014-12-24 2018-01-09 Gilead Sciences, Inc. compostos de isoquinolina para o tratamento de hiv
CN112239459B (zh) * 2019-07-19 2021-11-26 中国科学院上海药物研究所 稠环嘧啶氨基化合物、其制备方法、药物组合物及应用
CN115916759B (zh) * 2020-06-19 2025-07-15 泰州红云制药有限公司 取代喹唑啉类化合物、其制备方法、药物组合及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1235815A1 (en) * 1999-11-22 2002-09-04 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
MXPA05007503A (es) 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
US7691866B2 (en) 2003-10-16 2010-04-06 Novartis Vaccines And Diagnostics, Inc. 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase
EP2543376A1 (en) 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazine inhibitors of kinases
US7652051B2 (en) 2004-08-25 2010-01-26 Targegen, Inc. Heterocyclic compounds and methods of use
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
JP2008533166A (ja) 2005-03-16 2008-08-21 ターゲジェン インコーポレーティッド ピリミジン化合物および使用法
US7906522B2 (en) * 2005-04-28 2011-03-15 Kyowa Hakko Kirin Co., Ltd 2-aminoquinazoline derivatives
AU2006254825A1 (en) 2005-06-08 2006-12-14 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
AR060358A1 (es) * 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
JP2010514693A (ja) * 2006-12-22 2010-05-06 ノバルティス アーゲー Ｐｄｋ１阻害のためのキナゾリン

Also Published As

Publication number Publication date
JP2012514020A (ja) 2012-06-21
US8389530B2 (en) 2013-03-05
US20120004210A1 (en) 2012-01-05
SG172415A1 (en) 2011-07-28
PE20120424A1 (es) 2012-05-04
DOP2011000209A (es) 2011-09-30
CA2748319A1 (en) 2010-07-08
MA32968B1 (fr) 2012-01-02
NZ593949A (en) 2013-08-30
EP2381943A1 (en) 2011-11-02
ECSP11011204A (es) 2011-10-31
MX2011007064A (es) 2012-01-20
BRPI0924067A2 (pt) 2016-01-26
AU2009334869A2 (en) 2011-09-29
AU2009334869A1 (en) 2011-07-14
CN102333533A (zh) 2012-01-25
NI201100134A (es) 2012-03-06
ZA201104777B (en) 2012-03-28
KR20110120878A (ko) 2011-11-04
EA201101012A1 (ru) 2012-01-30
CR20110368A (es) 2011-12-02
CO6390105A2 (es) 2012-02-29
WO2010076238A1 (en) 2010-07-08
TN2011000319A1 (en) 2012-12-17
EA019110B1 (ru) 2014-01-30

Similar Documents

Publication Publication Date Title
GB0800035D0 (en) Compounds
IL231955A0 (en) Tetracycline compounds are substituted at the 7c position with fluorine
GB0804702D0 (en) Compounds
ZA201104777B (en) Substituted quinazoline compounds
ZA201008177B (en) Substituted quinazolines
IL219504A0 (en) Quinazoline compounds
GB0808944D0 (en) Substituted quinazolines
GB0808947D0 (en) Substituted quinazolines
GB0807103D0 (en) Compounds
GB0800367D0 (en) Compounds
GB0808951D0 (en) Substituted quinazolines
GB0808950D0 (en) Substituted quinazolines
GB0808953D0 (en) substituted quinazolines
GB0808952D0 (en) Substituted quinazolines
GB0810005D0 (en) Substituted quinazolines
GB0801220D0 (en) Compounds
GB0801265D0 (en) Compounds
HK1158546A (en) Substituted quinazoline compounds
IL210015A0 (en) Substituted cyclohexylidene-ethylidene-octahydro-indene compounds
GB0800961D0 (en) Compounds
GB0804064D0 (en) Compounds
GB0800841D0 (en) Compounds
GB0800455D0 (en) Compounds
GB0801596D0 (en) Compounds
GB0802191D0 (en) Compounds